MELA Sciences, Inc. (MELA)
Q2 2012 Earnings Call
August 7, 2012 4:30 PM ET
Joseph Gulfo – Chairman, President, CEO
Richard Steinhart – VP Finance, CFO, Treasurer
Josh Jennings – Cowen and Company
John Sullivan – Leerink Swann
Scott Gleason – Stephens
Dalton Chandler – Needham and Company
Greg Chodaczek – First Analysis
Good day, ladies and gentlemen, and welcome to the MELA Science second quarter financial results conference call. Today’s conference is being recorded. This presentation includes forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995.
These statements include but are not limited to our plans, objectives, expectations, and intentions or other statements that contain words such as expects, contemplates, anticipates, plans, intends, believes, assumes, predicts, and variations of such words or similar expressions that predict or indicate future events or trends, or that did not relate to historical matters.
These statements are based on current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurances that our beliefs or expectations will be achieved.
Actual results may differ materially from our beliefs or expectations due to financial, economic, business, competitive market, regulatory, or political factors, or conditions affecting the company and the medical device industry, in general, as well as more specific risks and uncertainties facing the company such as those set forth in its reports on Forms 10-Q and 10-K filed with the US Securities Exchange Commission.
Factors that might cause such differences include whether MelaFind achieves market acceptance given the uncertainties affecting companies in the medical device industry such as the company or any of these forward-looking statements may provide to be correct.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts